Showing results (201-210 of 214) with videos related to
Sort By:
Pageof 22
Nature Communications|December 31, 2024
Rapid lightsheet fluorescence imaging of whole Drosophila brains at nanoscale resolution by potassium acrylate-based expansion microscopyXuejiao Tian, Tzu-Yang Lin, Po-Ting Lin, et al.Hepatology (Baltimore, Md.)|July 1, 2025
Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in hepatocellular carcinomaChien-Hao Huang, Wei-Ting Ku, Jayashri Mahalingam, et al.Liver Cancer|October 22, 2024
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for OligoprogressionTsung-Hao Liu, San-Chi Chen, Kun-Ming Rau, et al.Journal of Medicinal Chemistry|April 30, 2014
Discovery of 4-aryl-N-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 inhibitors. Part I: optimization of in vitro potencies and pharmacokinetic propertiesYing-Shuan E Lee, Shih-Hsien Chuang, Lynn Y L Huang, et al.Journal of Medicinal Chemistry|August 5, 2010
Discovery of pyrrole-indoline-2-ones as Aurora kinase inhibitors with a different inhibition profileChao-Cheng Chiang, Yu-Hsiang Lin, Shu Fu Lin, et al.Liver Cancer|July 9, 2026
Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort StudyTeng-Yu Lee, Pei-Chang Lee, Ying-Chun Shen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2024
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus BevacizumabYing-Chun Shen, Tsung-Hao Liu, Alan Nicholas, et al.European Journal of Medicinal Chemistry|November 4, 2010
Synthesis and structure-activity relationship of 3-O-acylated (-)-epigallocatechins as 5α-reductase inhibitorsShu Fu Lin, Yu-Hsiang Lin, Mengju Lin, et al.European Journal of Medicinal Chemistry|March 1, 2020
Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapyShih-Hsien Chuang, Ying-Shuan E Lee, Lynn Y L Huang, et al.European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.Pageof 22